Onyx Pharms Amgen Drug Patent Portfolio
Onyx Pharms Amgen owns 1 orange book drug protected by 12 US patents Given below is the list of Onyx Pharms Amgen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | 27 Feb, 2033 | Active |
| US9511109 | Combination therapy with peptide epoxyketones | 21 Oct, 2029 | Active |
| USRE47954 | Combination therapy with peptide epoxyketones | 21 Oct, 2029 | Active |
| US7737112 | Composition for enzyme inhibition | 07 Dec, 2027 | Active |
| US7417042 | Compounds for enzyme inhibition | 20 Jul, 2026 | Active |
| US7232818 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
| US7491704 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
| US8129346 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
| US8207125 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
| US8207126 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
| US8207127 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
| US8207297 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
Latest Legal Activities on Onyx Pharms Amgen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Onyx Pharms Amgen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2024 | US9493582 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8207297 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8207125 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8207127 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8207126 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Aug, 2023 | US8129346 (Litigated) |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9493582 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Dec, 2021 | US7737112 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Aug, 2020 | US7491704 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Apr, 2020 | US9493582 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Feb, 2020 | US7417042 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2019 | US8207125 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2019 | US8207297 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2019 | US8207127 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2019 | US8207126 (Litigated) |
Onyx Pharms Amgen's Family Patents
Onyx Pharms Amgen drugs have patent protection in a total of 41 countries. It's US patent count contributes only to 26.7% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Onyx Pharms Amgen Drug List
Given below is the complete list of Onyx Pharms Amgen's drugs and the patents protecting them.
1. Kyprolis
Kyprolis is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
27 Feb, 2033
(8 years from now)
| Active |
| US9511109 | Combination therapy with peptide epoxyketones |
21 Oct, 2029
(5 years from now)
| Active |
| USRE47954 | Combination therapy with peptide epoxyketones |
21 Oct, 2029
(5 years from now)
| Active |
| US7737112 | Composition for enzyme inhibition |
07 Dec, 2027
(3 years from now)
| Active |
| US7417042 | Compounds for enzyme inhibition |
20 Jul, 2026
(1 year, 9 months from now)
| Active |
| US7232818 | Compounds for enzyme inhibition |
14 Apr, 2025
(6 months from now)
| Active |
| US7491704 | Compounds for enzyme inhibition |
14 Apr, 2025
(6 months from now)
| Active |
| US8129346 | Compounds for enzyme inhibition |
14 Apr, 2025
(6 months from now)
| Active |
| US8207125 | Compounds for enzyme inhibition |
14 Apr, 2025
(6 months from now)
| Active |
| US8207126 | Compounds for enzyme inhibition |
14 Apr, 2025
(6 months from now)
| Active |
| US8207127 | Compounds for enzyme inhibition |
14 Apr, 2025
(6 months from now)
| Active |
| US8207297 | Compounds for enzyme inhibition |
14 Apr, 2025
(6 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kyprolis's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List